Skip to main content
OpenTrials

Clinical trial condition

Glomerulonephritis, IGA

Explore clinical trials studying Glomerulonephritis, IGA. Study availability and eligibility vary by location and protocol.

190 public trials 56 recruiting studies
Refine in advanced search Browse all conditions

Glomerulonephritis, IGA trial results

Completed

Rituximab and RASi in Patients with IgAN

NCT04525729

Conditions
Autoimmune Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +14 more
Locations
  • Ruijin Hospital, Shanghai JiaoTong University School of Medicine Shanghai, Shanghai Municipality, China
View Trial Details
Completed

Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade

NCT02384317

Conditions
Autoimmune Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +9 more
Locations
  • Palo Alto, California, United States
  • San Francisco, California, United States
  • Reno, Nevada, United States
  • Chapel Hill, North Carolina, United States
View Trial Details
Completed

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

NCT03453619

Conditions
Autoimmune Diseases, C3 Glomerulonephritis, Connective Tissue Diseases, +18 more
Locations
  • Stanford University Stanford, California, United States
  • Children's Hospital Colorado Aurora, Colorado, United States
  • HealthONE Physician Care, Rocky Mountain Hospital for Children Denver, Colorado, United States
  • Washington Nephrology Associates Washington D.C., District of Columbia, United States
View all 17 locations
View Trial Details
Completed

Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)

NCT04541043

Conditions
Autoimmune Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +9 more
Locations
  • 13 Investigator sites Palo Alto, California, United States
  • 4 Investigator sites Buenos Aires, Argentina
  • 6 Investigator sites Melbourne, Australia
  • 3 Investigator sites Minsk, Belarus
View all 18 locations
View Trial Details
Completed

A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy

NCT04014335

Conditions
Autoimmune Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +9 more
Locations
  • IONIS Investigative Site Liverpool, New South Wales, Australia
  • IONIS Investigative Site St Leonards, New South Wales, Australia
  • IONIS Investigative Site Parkville, Victoria, Australia
  • IONIS Investigative Site Vancouver, British Columbia, Canada
View Trial Details
Completed

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

NCT03643965

Conditions
Autoimmune Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +9 more
Locations
  • University of Alabama at Birmingham, 1720 2nd Ave South Birmingham, Alabama, United States
  • Univ of Arizona, 1501 N Campbell Ave Tucson, Arizona, United States
  • Stanford University Medical Center, 777 Welch Rd Palo Alto, California, United States
  • Los Angeles Biomedical Research Institute at HUMC, 1124 W. Carson Street Torrance, California, United States
View all 142 locations
View Trial Details

Related conditions